In our studies, we observed not only a robust expression of NKp44 but also NKp30, in Vδ1+ T cells activated with TCR agonists and IL-15 (or IL-2); and both receptors enhanced γδ T cytotoxicity against tumor target cells (39, 73). The gene discussed is NCR3; the disease is neoplasm.